Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1323099 (sympathomimetic)
 2,957 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sotalol is a new beta-adrenoceptor blocking drug without membrane stabilizing activity, without intrinsic sympathomimetic activity and with a low cardio-depressive effect. This beta-blocking agent has an half-life much longer than the other beta-blockers (T 1/2 from 10 to 13 hours). The antihypertensive effect and tolerance of 160 mg tablets of sotalol were studied in 35 hypertensive patients aged 18 to 60 years. The drug was administred once daily in the morning. Sotalol prescribed as the only antihypertensive drug lowered the blood pressure to normal values in 21 cases with a single daily of 1 to 3 tablets. In 8 patients a partial response was obtained (25 % reduction of the initial systolic and diatolic pressure). Six patients did not respond. The clinical and biological tolerances were good; Sotalol was only discontinued in three cases. Sotalol appears to be an effective and well tolerated antihypertensive agent, specially for the treatment of moderate and recent essential hypertension in young patients.
 ...
PMID:[Treatment of hypertension with Sotalol (author's transl)]. 23 80

The beta-adrenoceptor blocking properties and pharmacokinetics of bucindolol 150 mg were compared to those of propranolol 80 mg and a placebo in a double-blind trial in 6 healthy volunteers. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressures and peak expiratory flow rate (PEFR) at rest and during vigorous exercise, and plasma renin activity (PRA) at rest, were measured before and at intervals up to 24 h after oral administration of the drugs. Bucindolol reduced exercise tachycardia and decreased exercise PEFR, thus behaving as a non-selective beta-adrenoceptor blocking drug. In contrast to propranolol, bucindolol did not reduce resting HR and PRA, probably because of its intrinsic sympathomimetic activity. It decreased resting DBP in relation to its peripheral vasodilator properties. The effects of bucindolol developed as early as 30 min after administration and lasted up to 24 h, whereas its Tmax and T 1/2 were 1.6 and 3.6 h respectively. Comparison of the time courses of plasma bucindolol and the cardiac beta-adrenoceptor blockade strongly suggests that in man bucindolol undergoes an extensive first-pass effect, leading to the formation of one or more active metabolites.
 ...
PMID:Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. 285 99